Serum neurofilament-light concentration and real-world outcome in MS

Anderson, Valerie, Bentley, Emily, Loveless, Sam ORCID: https://orcid.org/0000-0002-5124-4115, Bianchi, Lucia, Harding, Katharine E., Wynford-Thomas, Ray A., Joseph, Fady, Giovannoni, Gavin, Gnanapavan, Sharmilee, Robertson, Neil P. ORCID: https://orcid.org/0000-0002-5409-4909, Marta, Monica and Tallantyre, Emma C. ORCID: https://orcid.org/0000-0002-3760-6634 2020. Serum neurofilament-light concentration and real-world outcome in MS. Journal of the Neurological Sciences 417 , 117079. 10.1016/j.jns.2020.117079

Preview

PDF - Accepted Post-Print Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (796kB) | Preview

Abstract

Background Prognostication in multiple sclerosis (MS) remains challenging. Biomarkers capable of providing this information at diagnosis would be valuable in shaping therapeutic decisions. Measurement of neurofilament light (NfL) has shown promise in predicting clinical outcomes in established MS, but its ability to predict outcomes in real-world cohorts at diagnosis requires further validation. Methods We used linear regression to evaluate the relationship between serum NfL (sNfL), measured at the time of diagnosis with short-term (1-year) and medium-term (5-year) clinical outcomes in 164 people with MS from a real-world, population-based cohort. Cox proportional hazards regression was used to analyse the association between sNfL and subsequent hazard of relapse or sustained accumulation of disability (SAD). Analyses were adjusted for age and disease-modifying treatment (DMT). Results sNfL concentration at diagnosis was modestly associated with baseline EDSS score (β = 0.272, 95% CI 0.051 to 0.494, p = 0.016). However, no significant associations were found between baseline sNfL and odds of relapse at 12-months, 5-year EDSS change, or the hazard of relapse or SAD over 5 years follow-up. Dichotomising baseline sNfL according to the median sNfL did not change these findings. Conclusions sNfL appears to be of limited clinical utility in predicting future irreversible neurological disability in a largely untreated real-world population, and remains insufficiently validated to shape treatment decisions at the time of diagnosis. Further studies may be needed for sNfL to be considered as a prognostic marker in the MS clinic. However the masking effect of DMTs on the natural disease trajectory will continue to pose challenges.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG)
Publisher:	Elsevier
ISSN:	0022-510X
Date of First Compliant Deposit:	13 August 2020
Date of Acceptance:	31 July 2020
Last Modified:	07 Nov 2024 09:00
URI:	https://orca.cardiff.ac.uk/id/eprint/134200

Citation Data

Cited 12 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item